» Articles » PMID: 22207924

Serum HIF-1alpha and VEGF Levels Pre- and Post-TACE in Patients with Primary Liver Cancer

Overview
Journal Chin Med Sci J
Date 2012 Jan 3
PMID 22207924
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the expression levels of serum hypoxia inducible factor 1 alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) pre- and post-transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer (PLC), and correlations between prognosis factors and serum HIF-1alpha as well asVEGF levels.

Methods: Forty consecutive patients fulfilling diagnostic criteria for PLC undergoing TACE from March 2008 to May 2009 were enrolled into the study. The serum HIF-1alpha and VEGF levels of PLC patients pre- and 1 day, 1 week, 1 month post-TACE were analyzed using ELISA, and compared with that of 20 healthy volunteers. Patients were divided into complete response (CR) and partial response (PR), stable disease (SD), progressive disease (PD) groups according to the therapeutic efficacy. Pearson correlation was used to analyze the correlation between different clinical variables and serum HIF- 1alpha and VEGF levels before TACE, and correlation between serum HIF-1alpha and VEGF levels was also evaluated.

Results: The expression levels of serum HIF-1alpha and VEGF in PLC patients were 154.94 +/- 83.29 and 264.00 +/- 148.10 pg/mL pre-TACE, and both of them were significantly higher than those in control group (23.84 +/- 8.15 and 69.78 +/- 21.42 pg/mL, all P<0.01). One day after TACE, both serum HIF-1alpha (570.64 +/- 230.87 pg/mL) and VEGF levels (362.07 +/- 102.25 pg/mL) reached the peak values (all P<0.01). One week post-TACE, expression levels of them were decreased (198.62 +/- 92.11 and 283.52 +/- 145.46 pg/mL respectively), but still significantly higher than those before TACE (all P<0.01). The levels of both HIF-1alpha (133.96 +/- 57.02 vs. 255.74 +/- 123.44 pg/mL) and VEGF (150.96 +/- 84.89 vs. 368.95 +/- 161.90 pg/mL) in CR group 1 month post-TACE were significantly lower than those in PR+SD+PD group (all P<0.01). The level of serum HIF-1alpha was positively correlated with serum VEGF level (r=0.42, P<0.001). Both serum HIF-1alpha and VEGF levels were observed to be correlated with portal vein tumor thrombi (P<0.05) and metastasis (P<0.05).

Conclusion: The HIF- 1alpha and VEGF might play an important role in relapse of PLC. They might be considered as predictors of the efficacy ofTACE and metastasis of PLC.

Citing Articles

Tumor Suppressor miR-34a: Potential Biomarker of TACE Response in HCC.

Zavadil J, Juracek J, Cechova B, Rohan T, Husty J, Slaby O Cardiovasc Intervent Radiol. 2024; 48(1):26-37.

PMID: 39638971 DOI: 10.1007/s00270-024-03908-5.


[Efficacy and safety of transcatheter arterial chemoembolization followed by hepatic arterial infusion chemotherapy combined with TKI and PD-1 inhibitors as first-line treatment for advanced hepatocellular carcinoma].

Zhang L, Liu X, Hu X, Wang J, Yu X, Li G Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(9):1831-1838.

PMID: 39505352 PMC: 11744093. DOI: 10.12122/j.issn.1673-4254.2024.09.24.


Gelation embolism agents suppress clinical TACE-incited pro-metastatic microenvironment against hepatocellular carcinoma progression.

Song L, Zhu C, Shi Q, Xia Y, Liang X, Qin W EBioMedicine. 2024; 109:105436.

PMID: 39476535 PMC: 11567102. DOI: 10.1016/j.ebiom.2024.105436.


Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan.

Teng W, Wang H, Lin S Liver Cancer. 2024; 13(5):468-486.

PMID: 39435274 PMC: 11493393. DOI: 10.1159/000537686.


Prognostic Value of Preoperative MRI-derived 3D Quantitative Tumor Arterial Burden in Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization.

Peng G, Huang X, Wang Y, Cao X, Zhou X Radiol Imaging Cancer. 2024; 6(3):e230167.

PMID: 38607280 PMC: 11148827. DOI: 10.1148/rycan.230167.